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Participation of Hindbrain AMP-Activated Protein
Kinase in Glucoprivic Feeding
Ai-Jun Li, Qing Wang, and Sue Ritter
OBJECTIVE—To examine the role of AMP-activated protein
kinase (AMPK) in the control of glucoprivic feeding by hindbrain
catecholamine neurons.
RESEARCH DESIGN AND METHODS—Micropunched hind-
brain samples were collected from control and 2-deoxy-D-glucose
(2DG)-injected rats for Western blot analysis of phosphorylated
(activated) AMPK (pAMPK). Samples also were collected from
2DG-injected rats pretreated with anti-dopamine-b-hydroxylase
conjugated to saporin to lesion hindbrain catecholamine neurons.
In a second experiment, rats were given a fourth-ventricle injec-
tion of compound C (CC) or 5-aminoimidazole-4-carboxyamide
ribonucleoside (AICAR), an inhibitor and activator of AMPK, to
identify a role for AMPK in hindbrain neurons required for elic-
itation of 2DG-induced feeding.
RESULTS—Systemic 2DG stimulated food intake in controls but
not in catecholamine-lesioned rats. In controls, but not catechol-
amine-lesioned rats, 2DG also increased phosphorylated Thr172
at AMPKa subunits (pAMPKa) in hindbrain micropunches con-
taining catecholaminergic cell groups A1 through the middle re-
gion of C1 (A1–C1m). Increased pAMPKa was not observed in
the adjacent noncatecholaminergic ventromedial medulla or in
the A2–C2 catecholamine cell groups in the dorsal hindbrain.
Fourth-ventricle injection of CC attenuated 2DG-induced feeding
during the ﬁrst 2 h of the test, and AICAR alone increased food
intake only during the ﬁrst 60 min of the 4-h test.
CONCLUSIONS—Results indicate that AMPK in catecholamin-
ergic A1–C1m neurons is activated by glucoprivation. Therefore,
AMPK may contribute to the glucose-sensing mechanism by
which these neurons detect and signal a glucose deﬁcit in the
service of systemic glucoregulation. Diabetes 60:436–442, 2011
A
continuous supply of glucose is essential for
the function and survival of neurons in the
brain. Maintaining the brain’s glucose supply
depends on a number of glucoregulatory re-
sponses elicited by a glucose deﬁcit. Systemic injection of
2-deoxy-D-glucose (2DG), a competitive inhibitor of intra-
cellular glucose utilization (1), induces cellular glucopri-
vation and triggers a number of glucoregulatory responses.
Increased food intake is one of the most crucial responses
to a glucose deﬁcit. Studies using a selective retrogradely
transported catecholamine immunotoxin, anti-dopamine-
b-hydroxylase (DBH)-saporin (DSAP), have demonstrated
that catecholamine neurons innervating the medial hypo-
thalamus are required for elicitation of glucoprivic feeding
as well as for glucoprivation-induced corticosterone se-
cretion and suppression of estrous cycles (2–4) and for
glucoprivation-induced increases in arcuate nucleus neu-
ropetide Y (Npy) and agouti-related protein (Agrp) mRNAs
(5). A separate population that projects spinally mediates
the adrenal medullary response (2,6). Additional work
using a number of different approaches has shown that
the hindbrain contains cells capable of detecting a glu-
cose deﬁcit and eliciting feeding and other glucoreg-
ulatory responses (7–11) and suggests the possibility that
certain catecholamine neurons may themselves be glu-
coreceptive.
A number of ﬁndings indicate that the speciﬁc cate-
cholamine neurons required for glucoprivic feeding are
located in the ventrolateral hindbrain area containing the
rostral portion of cell group A1 and the caudal two-thirds
of group C1 (A1–C1). The A1–C1 neurons are potently
activated by glucoprivation (12–14), and they innervate
the hypothalamic areas involved in the control of metab-
olism and appetite (15). Furthermore, glucoprivic feeding
is blocked by simultaneous silencing in A1–C1 neurons
of the genes encoding the catecholamine biosynthetic en-
zyme, DBH, and the colocalized peptide, NPY, respec-
tively (16).
AMP-activated protein kinase (AMPK) is a highly
conserved serine/threonine kinase that is activated by an
increase of the cellular AMP-to-ATP ratio and is consid-
ered to be a sensor of cellular energy status (17–20). Upon
activation, AMPK inhibits ATP-consuming pathways and
stimulates ATP-generating pathways to restore cellular
energy balance. AMPK is expressed in brain regions in-
volved in the regulation of feeding behavior (21,22), and
a number of studies have shown that brain AMPK con-
tributes to the control of food intake and glucose homeo-
stasis. Food deprivation increases AMPK activity in the
hypothalamus, whereas refeeding inhibits it (23). A third-
ventricle injection of the AMPK activator 5-amino-
imidazole-4-carboxamide-1-b-D-ribofuranoside (AICAR) or
overexpression of AMPK in the hypothalamus increases
feeding and body weight (23,24). Activation of AMPK
requires phosphorylation of catalytic a-subunits at Thr172
(pAMPKa). Reports have shown that pAMPKa in the hy-
pothalamus is upregulated by insulin-induced hypoglyce-
mia or 2DG-induced glucoprivation (25–27) and that 2DG
enhances pAMPKa expression through decreasing cellular
ATP levels in cultured neuronal cells (28). Thus, we hy-
pothesized that AMPK in the hindbrain also contributes to
2DG-induced glucoprivic feeding and may be a part of the
glucose-sensing transduction mechanism. As a ﬁrst step
in testing this hypothesis, we measured pAMPKa in the
hindbrain catecholamine cell group A1–C1 after 2DG in-
jection in control rats and in rats with selective retrograde
immunotoxin lesion of these neurons. In addition, we ex-
amined the effect of enhancement or blockade of AMPK
activity in the hindbrain on glucoprivic feeding.
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ORIGINAL ARTICLERESEARCH DESIGN AND METHODS
MaleSDrats(SimonsenLaboratories,Gilroy,CA) werehousedindividuallyand
maintainedona12-h light/darkcycle (lights onat 0600h) with adlibitum access
to pelleted rodent food (F6 diet; Harlan Teklad, Madison, WI) and tap water. All
experimental procedures were approved by the Washington State University
Institutional Animal Care and Use Committee, which conforms to National
Institutes of Health guidelines.
Cannula implantation and fourth-ventricle injections. For the fourth-
ventricle cannula implantation, rats were anesthetized using 1.0 mL/kg body wt
of a ketamine/xylazine/acepromazine cocktail (5 mL ketamine HCl, 100 mg/mL,
Fort Dodge Animal Health, Fort Dodge, IA; 2.5 mL xylazine, 20 mg/mL, Vedco,
St. Joseph, MO; 1 mL acepromazine, 10 mg/mL, Vedco; and 1.5 mL 0.9% saline
solution) and placed in a stereotaxic device. A 26G cannula (15.0 mm long) was
implanted 1.55 mm rostral to the occipital suture, 60 mm lateral to midline and
6.3–6.4 mm ventral to the skull surface (29). Experiments were initiated 1
week later. Fourth-ventricle injections were delivered over a 3- to 5-min period
using a PB-600 repeating dispenser (Hamilton, Reno, NV). The position of the
fourth-ventricle cannula for each rat was conﬁrmed after the experiments by
staining hindbrain sections with cresyl violet. Only rats with a cannula cor-
rectly inserted into the fourth ventricle were used for data analysis.
Feeding tests. For glucoprivic feeding tests, rats were injected subcu-
taneously with 2DG (200 mg/kgbody wt in 0.9% sterile saline; Sigma-Aldrich, St.
Louis, MO) or with 0.9% sterile saline as the control. Food was removed at 0800
h, 2 h before the injections. Food intake was measured beginning immediately
after the injection and at various intervals thereafter, as indicated. The AMPK
inhibitor, compound C (CC; Sigma-Aldrich), was dissolved in DMSO (3 mg/mL)
and was injected into the fourth ventricle at a volume of 1 mL per rat 10–15
min before 2DG injection. At this concentration and volume, nonspeciﬁc
effects of DMSO on feeding were not observed. The AMPK activator AICAR
(Sigma-Aldrich) was dissolved in saline and injected into the fourth ventricle
at a dose of 20, 100, 300 (or 500) nmoL per rat in 3 (or 5) mL saline.
DSAP microinjection and DBH immunohistochemistry. The immunotoxin
DSAP (82 ng/200 nL; Advanced Targeting Systems, San Diego, CA) or control
unconjugated saporin (SAP) (17.2 ng/200 nL), dissolved in 0.1 mol/L PBS (pH
7.4), was infused bilaterally through a pulled-glass capillary pipette (30-mm tip
diameter) positioned stereotaxically just dorsal to the targeted site in the
paraventricular hypothalamic nucleus (PVH). Solutions were delivered using a
picospritzer (Parker, Cleveland, OH). Stereotaxic coordinates for the PVH in-
jection site were 1.8 mm caudal and 6 0.45 mm lateral to bregma and 7.3–7.4 mm
ventral to dura mater (29). The amount of unconjugated SAP in the control
solution approximated the amount of SAP present in the DSAP conjugate
(21%), as indicated in the manufacturer’s product information. Previous work
comparing SAP and uninjected controls demonstrated that SAP did not pro-
duce behavioral or signiﬁcant histological signs of toxicity (2). Glucoprivic
feeding induced by 2DG (200 mg/kg) was tested 3 weeks after DSAP or SAP
injections. One week later, expression of pAMPKa and total AMPKa in hind-
brain after the 2DG injection was measured. The DSAP lesion was evaluated
by Western blot analysis of tyrosine hydroxylase (TH) expression in hindbrain
sites of interest and in a separate group of lesioned rats using immunohisto-
chemistry (IHC) staining to detect DBH-positive cell bodies. Two methods
were used to conﬁrm the DSAP lesion because we knew that Western blot
analysis would detect the TH present in the punched sample from terminals
and processes of unlesioned catecholamine neurons not targeted by PVH
DSAP injection. Thus, Western blots of TH would not reﬂect the destruction of
catecholamine cell bodies in the lesion site as accurately as IHC.
For IHC, brains were sectioned coronally into four serial sets (40-mm
thickness) and stained using standard avidin-biotin-peroxidase IHC techniques
(13). Cell bodies expressing DBH were detected by murine anti-DBH antibody
(1:10,000; Millipore, Billerica, MA) and counted in three consecutive sections
(29) at each of four hindbrain regions.
Micropunch and dissection of hindbrain tissues. Tissue sites containing
catecholamine cell groups were micropunched or dissected from hindbrain for
Western blot. Catecholamine cell groups are deﬁned according to the Paxinos
and Watson (1998) rat brain atlas (29). However, we refer to the middle portion
of C1 as C1m, which extends from 12.72 to 12.30 mm caudal to bregma.
At designated times after treatment, rats were anesthetized deeply with
halothane (Halocarbon Products, North Augusta, SC) and were quickly de-
capitated. The brain was removed and frozen on dry ice. In 2DG-induced AMPK
experiments, a2-mm-thick coronal section was cut, using obex (deﬁned here as
the caudal border of the area postrema) to locate the caudal border of the slice
(0–2.0 mm rostral to obex). Then, the desired regions from this 2-mm-thick
slice were micropunched with a stainless steel sample corer that had a 1.0-mm
inner diameter (Fine Science Tools, Foster City, CA). Tissue punches were
collected from three areas (from A1–C1m, from an [noncatecholamine] area
medial to A1–C1m [ventromedial medulla (VMM)], and from A2–C2 in the
nucleus of the solitary tract [NTS]).
Micropunched samples were quickly placed into a radioimmunoprecipitation
assay (RIPA) buffer for protein isolation. The accuracy of the punches was
conﬁrmed by Western blot using antibodies against enzymes for catecholamine
synthesis (DBH and TH). Representative images of DBH and TH Western blots
for A1–C1m, VMM, and A2–C2 tissue punches were shown in Fig. 1. For all rats,
both DBH and TH expression were expressed more strongly (more than three
times) in A1–C1m and A2–C2 samples than in the VMM samples, indicating the
accuracy of the punches.
In AICAR-induced AMPK experiments, two 2-mm-thick coronal sections
were cut, using obex to locate the position of the cuts (0–2.0 and 2.0–4.0 mm
rostral to obex, respectively). Then, the two slices were divided into the dorsal
and ventral parts. Slice 1, the dorsal part, included A2, C2, and the NTS. Slice 1,
the ventral part, included A1–C1m. Slice 2, the dorsal part, included A2 and
C2. Slice 2, the ventral part, included C1r and A5. Tissue sections were quickly
placed into RIPA buffer for protein isolation and then used for Western blot.
Western blot. The method was modiﬁed from our previous reports (30,31).
Hindbrain tissues were ﬁrst incubated with RIPA buffer (50 mmol/L Tris, pH
8.0; 150 mmol/L NaCl; 1.0% (Octylphenoxy)polyethoxyethanol; 0.5% sodium
deoxycholate; and 0.1% SDS), with 1 mmol/L sodium ortho-vanadate, 1 mmol/L
okadiac acid, and 1/10 (vol/vol) protease inhibitor cocktail (Roche Diag-
nostics, Penzberg, Germany) for 30 min on ice. After centrifugation (14,000
rpm for 15 min at 4°C), an equivalent amount of protein (20 mg per lane) for
each sample was separated by SDS-PAGE. The resolved proteins on the gel
were transferred to a nitrocellulose membrane (Amersham, Piscataway, NJ).
The membranes were blocked in 5% nonfat dry milk in Tris-buffered saline/
0.05% Tween 20 and incubated with one of the following primary antibodies in
FIG. 1. Tissue micropunches from the hindbrain slices. A: Coronal
section of rat hindbrain (Paxinos and Watson [29]) showing the posi-
tions of each 1.0-mm-diameter circular punches used for Western blots.
Punches 1, 2, or 3 included A1–C1m, VMM, or A2–C2, respectively. B
and C: Immunoblots of DBH, TH, and b-actin from different tissue
micropunches are indicated in A. Higher expression levels of DBH and
TH were found in punch 1 (A1–C1m) tissue (B) or punch 3 (A2–C2)
tissue (C) than in the adjacent punch 2 (VMM) tissue in all individual
rats. AP, area postrema; CC, central canal; py, pyramidal tract; sp5,
spinal trigeminal tract.
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Tris-buffered saline/0.05% Tween 20, incubated in goat anti-rabbit IgG, goat
anti-murine IgG, or donkey anti-goat IgG antibody conjugated with peroxidase
(1:4,000; DakoCytomation, Glostrup, Denmark) and developed with the en-
hanced chemiluminescence method (Amersham) and exposed to X-OMAT ﬁlm
(Kodak, Rochester, NY). The following antibodies were used: murine anti–b-
actin (1:10,000; Sigma-Aldrich), rabbit anti-AMPKa (1:1,000; Santa Cruz Bio-
tech, Santa Cruz, CA), rabbit anti-pAMPKa (Thr172) (1:1,000; Millipore), goat
anti-DBH (1:600; Santa Cruz Biotech), and murine anti-TH (1:6,000; Millipore).
Densitometric analysis of blots was performed using Scion Image software
(Scion, Frederick, MD). The intensity of each band for each protein was
quantiﬁed and normalized with housekeeping gene b-actin expression in the
same membrane. The levels of total AMPKa or pAMPKa were expressed as
a percentage over that in the rats injected with saline.
Statistical analysis. All results are presented as means 6 SEM. For statistical
analysis of data, we used unpaired t test or one-way ANOVA using SigmaStat
(Systat Software, San Jose, CA). After signiﬁcance was determined by ANOVA,
multiple comparisons between individual groups were tested using a post hoc
Fisher protected least signiﬁcant difference (PLSD) test. P = 0.05 or P , 0.05
was considered to be statistically signiﬁcant.
RESULTS
2DG increased pAMPKa expression in A1–C1m. As
shown in Fig. 2A, pAMPKa was signiﬁcantly increased
by 2DG in ventrolateral medulla punches, which included
A1–C1m, 45 min after the injection (193.6 6 13.8% in the
2DG group vs. 100.0 6 6.1% in the saline group; P , 0.001)
and returned to near-control values 2 h after the injection
(113.1 6 8.1% of control). This enhancement was site
speciﬁc. In the VMM, a region adjacent to the A1–C1m,
pAMPKa was unchanged by 2DG (Fig. 2A). In the A2–C2
region, pAMPKa was somewhat increased at both 45 min
and 2 h after 2DG injection, but the increased levels did
not differ signiﬁcantly from control values (P . 0.4 be-
tween groups). Total AMPKa expression was not altered
by 2DG in any of the sampled regions at the time points
tested (Fig. 2B).
Lesion of hindbrain neurons by DSAP abolished 2DG-
induced pAMPKa expression. After PVH DSAP injec-
tions, catecholamine neurons in the hindbrain were greatly
reduced, as indicated by the attenuation of 2DG-induced
glucoprivic feeding (Fig. 3A) and decreased TH expression
(Fig. 3B) in the hindbrain. SAP rats ate ﬁvefold more food
during the 4-h period after 2DG injection than after the
saline injection (P , 0.001), whereas DSAP rats ate almost
the same amount of food in the two tests (P . 0.1). In
a separate experiment, food intake was measured at both 2
and 4 h after 2DG injection. Between 0 and 2 h, SAP rats
ate 4.8 6 1.1 g vs. 0.2 6 0.1 g for DSAP rats, whereas
between 2 and 4 h, DSAP rats ate 0.4 6 0.1 g vs. 0.5 6 0.1 g
for SAP rats (n = 5 for each group). 2DG increased the
pAMPKa expression in A1–C1m in the SAP rats at 45 min
after 2DG injection (P , 0.01), whereas 2DG had no effect
on pAMPKa expression in the DSAP rats (Fig. 3C). DSAP
rats, treated with saline or 2DG, had slightly higher
pAMPKa expression levels than SAP saline rats, but there
was no signiﬁcant difference between the two DSAP groups.
No signiﬁcant changes were found in the total AMPKa ex-
pression levels between SAP and DSAP rats, regardless of
whether they were injected with saline or 2DG (Fig. 3D).
In DSAP rats, TH expression in A1–C1m, by Western
blot, was decreased to 44.2% of the level in SAP controls
(P , 0.001) (Fig. 3B). TH expression did not differ for A1–
C1m in SAP saline and non–SAP saline rats (100.0 6 10.2%
vs. 94.3 6 4.6%; n =6 –7 rats; P . 0.6), indicating that SAP
injections did not retrogradely lesion hindbrain catechol-
amine neurons. Parallel IHC analysis of the lesion (Fig. 4)
showed that PVH DSAP injection eliminated DBH-positive
ﬁbers in the PVH and signiﬁcantly reduced the number
of DBH-positive cells in the A1–C1m, which heavily in-
nervate the PVH, as shown previously (15,32). The number
of DBH-positive cells was reduced in the A1–C1m to 21.5%
of the number present in SAP rats.
Inhibition of AMPK activity in the hindbrain impaired
glucoprivic feeding. Preinjection of CC signiﬁcantly
suppressed glucoprivic feeding during the ﬁrst 2 h after
2DG injection to 70.6% of the amount consumed by rats
injected with 2DG alone (P , 0.05) but did not suppress
2DG-induced feeding at 4 h (81%, P . 0.1) or 7 h (97.1%,
P . 0.8) after injection (Fig. 5).
Effect of hindbrain activation of AMPK on food
intake. To reveal whether activation of hindbrain AMPK
FIG. 2. Total and phosphorylated forms of AMPKa in three hindbrain regions after 2DG injection. Tissue homogenates were obtained 45 or 120 min
after saline (control) or 2DG (200 mg/kg s.c.) injection. Equivalent amounts of protein were subjected to SDS-PAGE and immunoblotted with anti-
pAMPKa, anti-total AMPKa, or anti–b-actin antibody. A: Upper panel: immunoblots of pAMPKa and b-actin in A1–C1m, VMM, and A2–C2 regions
with saline or 2DG injection. Lower panel: quantitative data. B: Upper panel: immunoblots of total AMPKa and b-actin in A1–C1m and A2–C2
regions. Lower panel: quantitative data. To compare expression levels of these proteins, the intensity of each band was quantiﬁed and normalized
with b-actin and expressed as the percentage of saline control rats. *P < 0.01 vs. the control saline-injected rats. Fisher PLSD test after one-way
ANOVA (n = eight rats for each group).
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injected into the fourth ventricle. Figure 6 shows that
AICAR at 20 and 100 nmol per rat increased feeding only
during the ﬁrst 60 min after the injection (all P = 0.05 or
P , 0.05). The higher dose, 500 nmol, did not appear to
alter food intake at any time point. The time course of the
AICAR response was much more transient than that pro-
duced by 2DG or insulin-induced hypoglycemia. Western
blot was performed to check whether such doses of
AICAR efﬁciently increase AMPK activity in the hindbrain.
As shown in Table 1, AICAR doses $100 nmol per rat
signiﬁcantly increased pAMPKa expression in the hind-
brain 35–45 min later. AICAR was more effective in in-
creasing pAMPKa in the ventral than in the dorsal
hindbrain (Table 1), in both slice 1 (0–2.0 mm rostral to
obex) and slice 2 (2.0–4.0 mm rostral to obex).
DISCUSSION
In the current study, we found that systemic 2DG treat-
ment increased hindbrain AMPK phosphorylation at the
Thr172 of the a-subunit detected by our antibody. pAMPKa
expression was signiﬁcantly elevated only in the A1–C1m
region of the ventrolateral medulla but not in neighbor-
ing noncatecholaminergic VMM. Expression of pAMPKa
also tended to increase in A2–C2, but there the increase
was not statistically signiﬁcant. The fact that pAMPKa
expression levels were not increased by 2DG in the A1–
C1m region in rats in which catecholamine neurons in this
region were lesioned retrogradely by PVH DSAP injection
suggests that the AMPK phosphorylation induced by 2DG
in SAP controls occurs in A1–C1m catecholamine neurons.
The fact that this same DSAP lesion also abolished the
glucoprivic feeding response is consistent with a func-
tional role for AMPK in mediation of glucoprivic feeding.
AMPK is a universal cellular energy sensor, present in
both peripheral tissues and throughout the brain. There-
fore, one question that immediately arises from our results
FIG. 3. Glucoprivic feeding and AMPK expression in DSAP- or SAP-injected rats. A: Food intake during the 4-h period after 2DG (200 mg/kg s.c.) or
saline (Sal) injection in SAP and DSAP rats. *P < 0.001 vs. SAP rats with saline injection (n = 16 rats per group). B: TH expression levels in A1–
C1m regions in SAP and DSAP rats, measured by Western blot. The level of TH in SAP rats, normalized to b-actin, was used as 100%. *P < 0.001 vs.
SAP rats (n = 16 rats per group). C: Upper panel: immunoblots of pAMPKa and b-actin in A1–C1m regions 45 min after saline or 2DG injection.
Lower panel: quantitative pAMPKa data, normalized to b-actin. *P < 0.05 vs. saline-injected SAP rats; #P < 0.05 vs. 2DG-injected SAP rats. Fisher
PLSD test after one-way ANOVA (n = eight rats per group). D: Upper panel: immunoblots of total AMPKa and b-actin in A1–C1m regions 45 min
after saline or 2DG injection. Lower panel: quantitative data, normalized to b-actin (n = eight rats per group).
FIG. 4. Lesion effect of DSAP on hindbrain catecholamine neurons. A:
Representative IHC images of DBH staining in a SAP-injected (a and c)
or DSAP-injected (b and d) rat in PVH (a and b) or the hindbrain A1/C1
region (c and d). Scale bar = 0.5 mm. B: DBH-positive cells in each of the
hindbrain regions. *P < 0.01 vs. SAP rats (n = ﬁve rats in each group).
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vation was apparent only in the A1–C1m tissue punch. One
would expect that ubiquitous reduction in glucose utiliza-
tion after systemic 2DG treatment would activate AMPK in
many neurons. However, based on Fos expression as an
indicator of activation, relatively few neurons are activated
by glucoprivation. Furthermore, increased Fos in many
other brain areas is reduced or abolished when hindbrain
catecholamine neurons are destroyed by DSAP (2). Hence,
it is clear that A1–C1 neurons are more responsive to
glucoprivation than other brain neurons, including those
that are downstream in the glucoregulatory circuitry.
Therefore, a potential answer to this question is that cat-
echolamine neurons in the A1–C1m region are more sen-
sitive to a glucoprivic challenge than most neurons. This
possibility is consistent with previous reports showing that
A1–C1m neurons are more sensitive than most other cat-
echolamine neurons to glucoprivation-induced increases
in expression of c-Fos, Npy, and Dbh mRNA (2,12,13).
These results suggest that AMPK may be phosphorylated
at a higher glucose level in these catecholamine neurons
than in many other neurons in part because their activity is
increased, as opposed to reduced or not altered, by a glu-
cose deﬁcit, causing them to generate an ATP deﬁcit more
rapidly.
The above question is important in considering whether
the pAMPK is a consequence of increased neuronal ac-
tivity during glucoprivation or whether this signal is a
component of the glucoreceptive transduction mechanism.
The effects of CC on glucoprivic feeding suggest that the
elevated pAMPK may be related more to activation of the
neurons than to the transduction mechanism for sensing
glucoprivation. CC-induced attenuation of 2DG-induced
feeding had a transient effect, and rats completely com-
pensated for the brief reduction of food intake during the
ensuing hours of the feeding test. If AMPK phosphory-
lation represented an adequate stimulus for detecting
glucoprivation, one might have expected a reversal or at-
tenuation of feeding that was uncompensated. Thus, it
appears as if the CC did not block a transduction process
or reduce glucoprivic signal strength but rather reduced
the rate of translation to a behavioral response, possibly by
reducing the cellular metabolic rate of the essential cate-
cholamine neurons. Likewise, a fourth-ventricle injection
of AICAR stimulated feeding only during the ﬁrst 60 min
after injection. The brevity of these effects may be attrib-
utable to differing pharmacokinetics of the 2DG, CC, and
AICAR. However, this explanation does not account for
the fact that 2DG injection produces long-lasting effects on
feeding but produced a relatively transient activation of
pAMPKa expression in the A1–C1m region. Indeed, it is
known that the feeding response and increased activation
of hindbrain catecholamine neurons (as measured by hy-
pothalamic norepinephrine turnover) persists even after
the return of normoglycemia, .6 h after 2DG- or insulin-
induced hypoglycemia, if nutrients are withheld during the
glucoprivic episode (33–36). Additional work will be re-
quired to determine how AMPK phosphorylation and its
downstream effects in A1–C1m and other neurons are re-
lated to the stimulation and time course of glucoprivic
feeding.
Although the results of pharmacological AMPK manip-
ulations do not provide strong support for a role in
transduction of the glucoprivic signal, several experimen-
tal observations have linked AMPK activation with tran-
scriptional changes appropriate to increasing food intake.
First, overexpression of the dominant-negative AMPKa
subunits in the ventromedial hypothalamus suppresses
food intake, reduces body weight, and decreases expres-
sion of the orexigenic neuropetide genes Npy and Agrp in
the arcuate nucleus, whereas expression of constitutively
active AMPKa subunits in that region increases feeding,
body weight, and enhances the fasting-induced increase of
Npy and Agrp in the arcuate nucleus (23). Injection of
AICAR into the lateral ventricle enhances Npy expression
in the hypothalamus, as shown by Northern blot (37). Our
FIG. 5. Effect of CC, an AMPK inhibitor, on 2DG-induced feeding. CC or
the control solvent, DMSO, was injected into the fourth ventricle 10–15
min before 2DG (200 mg/kg s.c.) or saline (Sal) injection. Food intake
was measured for the next 7 h. *P < 0.05 vs. DMSO-Sal group; #P < 0.05
vs. DMSO-2DG group. Fisher PLSD test after one-way ANOVA (n = eight
rats in each group).
FIG. 6. Effect of hindbrain AMPK activation on food intake. Saline
(Sal) or different doses of the AMPK activator, AICAR, were injected
into the fourth ventricle. Food intake was measured after the injection.
*P = 0.05 or P < 0.05 vs. the saline group. Fisher PLSD test after one-
way ANOVA (n =5 –8 rats per group).
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gene expression also is a target of AMPK in the hindbrain.
Studies have shown that Dbh and Npy are colocalized in
A1–C1 catecholamine neurons (15,32) and are both re-
quired for glucoprivic feeding (2,3,12–14,38). Glucopriva-
tion enhances expression of these genes in A1–C1 neurons
(12,13). Simultaneous silencing Npy and Dbh by injection
of small-interfering mRNA into the A1–C1 region blocks
feeding in response to systemic glucoprivation but fails to
block feeding when either of these genes is blocked sep-
arately (16). Npy in A1–C1 catecholamine neurons would
be a feasible target of AMPK because it appears to be in
the hypothalamus.
In the current study, we found a signiﬁcant enhance-
ment of pAMPKa by 2DG in the ventral (including A1, A1/
C1 overlap, and C1m), but not in dorsal, hindbrain
micropunches (including A2, C2, and the NTS). The neu-
rons in the ventral hindbrain regions also were more sen-
sitive to AMPK activation because AICAR injection into
the fourth ventricle increased pAMPKa expression in the
ventral but not the dorsal part of the hindbrain. In contrast,
Hayes et al. (39) have reported an enhancement of
pAMPKa in rat NTS after 24–48 h of food deprivation. They
did not report results from ventral hindbrain samples.
However, the fact that their dorsal hindbrain results differ
from ours deserves comment. First, the differences may be
attributed to the differing treatments used in these two
studies. Food deprivation for 24–48 h does not necessarily
produce glucoprivation. Food deprivation over this period
alters nutrient and gastrointestinal signals known to act on
the vagus nerve and/or the NTS (40) and are a likely stim-
ulus for AMPK activation, whereas the major responses
to glucoprivation occur by direct effects of glucopriva-
tion within the brain. In addition, differences between
these studies may be attributed to tissue sampling. Our
dorsal hindbrain tissue punches included the entire extent
of the NTS in order to sample both the A2 and C2 cell
groups. Hayes et al. (39) found, however, that the caudal
NTS at the level of the area postrema was sensitive to CC
exposure, whereas the rostral NTS was not. If this differ-
ential response also occurs during glucoprivation, then our
sampling method may have diluted the pAMPK signal to
a nonsigniﬁcant level. In support of this, we found that
pAMPKa expression was increased by ~30% in the A2–C2
micropunches at both 45 min and 2 h after the 2DG
treatment.
Basal levels of pAMPKa in DSAP rats were slightly en-
hanced in the A1–C1m compared with SAP rats. The
mechanisms underlying this apparent slight enhancement
and the cell types contributing to this increase were un-
clear in the current study. One possibility is that activated
glia cells, which persist for prolonged periods after neu-
ronal destruction, were present in the A1–C1 area as a
correlate of catecholamine neuron degeneration and may
have contributed to enhancement of basal AMPK phos-
phorylation levels. Regardless of the cell type responsible,
it is clear from the current study that this enhanced basal
pAMPKa did not enhance, and therefore presumably was
not related to, glucoprivic feeding.
In summary, we found that 2DG-induced glucoprivation
activated pAMPKa in the hindbrain region containing
A1–C1m catecholamine neurons. This activation was site
speciﬁc (it did not occur in adjacent noncatecholaminergic
tissue). Both 2DG-induced glucoprivic feeding and the
enhancement of pAMPKa in the A1–C1m were completely
abolished by retrograde DSAP lesion of A1–C1m neurons,
suggesting a major contribution of these neurons to the
pAMPK enhancement. Activation of AMPK by fourth ven-
tricular AICAR induced a brief feeding response, and
preinhibition of hindbrain AMPK activity by CC brieﬂy
impaired the feeding response to 2DG. These results sug-
gest that AMPK may contribute to the functions of A1–C1
catecholamine neurons during glucoprivation and may in-
dicate a role for AMPK as a glucosensory transduction
mechanism for the initiation of systemic glucoregulatory
responses.
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TABLE 1
Expression levels of pAMPKa and total AMPKa in the hindbrain after AICAR injection
Dose of AICAR (nmol per rat)
Region 0 20 100 300–500
Slice 1, dorsal part
pAMPKa 100.0 6 2.6 100.3 6 15.8 116.0 6 22.5 100.3 6 12.8
Total AMPKa 100.0 6 1.5 111.3 6 3.1 124.3 6 6.3 111.1 6 8.6
Slice 1, ventral part
pAMPKa 100.0 6 5.1 115.4 6 8.6 159.5 6 19.1* 191.8 6 24.8†
Total AMPKa 100.0 6 1.4 101.6 6 10.3 108.3 6 6.5 106.2 6 5.8
Slice 2, dorsal part
pAMPKa 100.0 6 4.2 87.3 6 18.5 111.3 6 8.7 120.0 6 17.0
Total AMPKa 100.0 6 7.3 104.6 6 13.2 118.9 6 7.5 107.8 6 2.3
Slice 2, ventral part
pAMPKa 100.0 6 5.9 111.4 6 8.1 143.9 6 11.7* 159.5 6 17.4†
Total AMPKa 100.0 6 0.6 103.0 6 2.3 110.0 6 2.6 105.6 6 5.2
Data are means 6 SEM. Expression levels of pAMPKa and total AMPKa (both normalized to b-actin expression) quantiﬁed by Western blot
from dissected hindbrain tissues collected 35–45 min after an injection of AICAR (0, 20, 100, or 300–500 nmol per rat in saline) into the fourth
ventricle. *P , 0.05; †P , 0.01 vs. the control saline-injected rats (as 100%) by Fisher PLSD test after one-way ANOVA (n = 4 rats per group).
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